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Abstract
Background: Although protein binding is a reversible phenomenon, it is assumed that antibacterial activity is exclusively
exerted by the free (unbound) fraction of antibiotics.
Methodology/Principal Findings: Activity of cefditoren, a highly protein bound 3
rd generation cephalosporin, over 24h
after an oral 400 mg cefditoren-pivoxil bid regimen was studied against six S. pneumoniae strains (penicillin/cefditoren MICs;
mg/ml): S1 (0.12/0.25), S2 (0.25/0.25), S3 and S4 (0.5/0.5), S5 (1/0.5) and S6 (4/0.5). A computerized pharmacodynamic
simulation with media consisting in 75% human serum and 25% broth (mean albumin concentrations=4.8560.12 g/dL)
was performed. Protein binding was measured. The cumulative percentage of a 24h-period that drug concentrations
exceeded the MIC for total (T.MIC) and unbound concentrations (fT.MIC), expressed as percentage of the dosing interval,
were determined. Protein binding was 87.1%. Bactericidal activity ($99.9% initial inocula reduction) was obtained against
strains S1 and S2 at 24h (T.MIC=77.6%, fT.MIC=23.7%). With T.MIC of 61.6% (fT.MIC=1.7%), reductions against S3
and S4 ranged from 90% to 97% at 12h and 24h; against S5, reduction was 45.1% at 12h and up to 85.0% at 24h; and
against S6, reduction was 91.8% at 12h, but due to regrowth of 52.9% at 24h. Cefditoren physiological concentrations
exerted antibacterial activity against strains exhibiting MICs of 0.25 and 0.5 mg/ml under protein binding conditions similar
to those in humans.
Conclusions/Significance: The results of this study suggest that, from the pharmacodynamic perspective, the presence of
physiological albumin concentrations may not preclude antipneumococcal activity of highly bound cephalosporins as
cefditoren.
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Introduction
Antibiotics kill or inhibit the growth of bacteria by well known
mechanisms of action. While in vitro antibiotics interact directly
with bacteria without interference, in vivo (whether in natural or
experimental infection) antibiotic and bacteria interactions are
more complex due to the presence of serum proteins acting as an
interface. Characterization of interactions between antibiotics and
proteins is essential in the assessment of pharmacodynamic
implications on antibacterial activity. While some serum proteins,
as gammaglobulins and complement enhance the antipneumo-
coccal activity of b-lactams as 3
rd generation cephalosporins [1,2],
others as albumin produce limitations in antibacterial activity in
highly protein bound agents. However, although it is generally
accepted that only the unbound fraction of the antibiotic is active
in vitro (and presumably in vivo), the quick reversibility of the
protein drug binding indicates that the presumed limitations of
antimicrobial activity can be far from absolute, also for highly
protein bound antibiotics [3].
Results of previous studies focusing on the effects of protein
binding on antimicrobial activity against gram-positive microor-
ganisms ranged from impairment to delay [4,5] or even increase of
activity [6]. As with other antibiotics [7], attempts to interpret
cefditoren pharmacodynamics using reported percentages of
protein binding can be inappropriate [8]. In the case of b-lactams
and Streptococcus pneumoniae, 33% time above the minimum
inhibitory concentration (T.MIC) has been previously used as a
bacteriostatic endpoint [9] and 40% T.MIC as the predictive
value for clinical cure in humans [10]. The pharmacodynamic
parameter predicting b-lactam efficacy (T.MIC) is usually based
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2717on free-drug concentrations extrapolated from total drug concen-
trations by considering the protein binding, thus estimating
antibiotic activity under the most stringent conditions.
Cefditoren is a third generation oral cephalosporin exhibiting in
vitro higher intrinsic activity than cefotaxime against S. pneumoniae
[11,12], a peak serum concentration of 4.2 mg/ml after a 400 mg
single dose, a protein binding rate of 88% [13], and clinical
efficacy in respiratory tract infections [14,15].
Computerized pharmacodynamic devices allow the study of
antibacterial activity along the dosing interval of simulated serum
concentrations, after standard dosing regimens, against specific
strains. Conclusions on antibiotic therapeutic activity (eradication
and subsequent clinical cure), and its pharmacodynamic predic-
tion, against these specific strains (with high MIC to the target
antibiotic) cannot be drawn from clinical trials due to the scarce
number of patients infected with these strains. The aim of this
study was to evaluate the bactericidal activity over 24h of
simulated serum concentrations of cefditoren obtained after an
oral 400 mg cefditoren-pivoxil bid regimen against penicillin non-
susceptible S. pneumoniae in an in vitro pharmacodynamic
simulation with human serum containing albumin physiological
concentrations.
Results
Figure 1 shows target and experimental concentrations of
cefditoren in the simulation process. Experimental pharmacokinetic
parametersobtainedwere:Cmax=4.160.2 mg/ml,Tmax=2.860.0 h,
t1/2=1.660.1 h, and AUCall=14.360.8 mg/ml6 h. Mean albumin
concentration was 4.960.1 g/dl at 0h, 4.860.2 g/dl at 12h and
4.860.1 g/dl at 24h. pH ranged from 7.4 to 7.8. Protein binding of
cefditoren in the media used in the simulation (75% non-heat
inactivated human serum and 25% Mueller-Hinton broth supple-
mented with 5% lysed sheep blood; HS-SMH) was 85.761.8% for
4 mg/ml, 88.260.6% for 0.5 mg/ml, and 87.561.2% for 0.125 mg/
ml (mean 87.161.3%; coefficient of variation=0.0149).
Susceptibilities of strains to penicillin and cefditoren and
serotypes are shown in Table 1. The same MIC values were
found prior and after the simulations carried out.
Figure 2 shows per strain mean bacterial counts over 24h, and
Figure 3, mean changes in log10 cfu/ml at 12h and 24h in
antibiotic-free and cefditoren simulations. All strains but S6
exhibited higher reduction in viable counts (log10 cfu/ml) at 24h
than at 12h.
Table 1 shows experimental cumulative percentage of a 24 h
period that drug concentrations exceeded the MIC for total
(T.MIC) and unbound concentrations (fT.MIC) expressed as
percentage of the dosing interval, initial inocula, times to obtain
90% (T90%), 99% (T99%) and 99.9% (T99.9%) reductions in initial
inocula, maximal reduction within the dosing interval (i.e, 12h)
and percentages of reduction at 12h and 24h. T90% was #6h for
all strains regardless the 0.25 or 0.5 mg/ml value of cefditoren
MIC, T99% was 4h for strains S1, S2 and S3 (MICs of 0.25, 0.25
and 0.5 mg/ml, respectively), and T99.9% was 6h for the two strains
exhibiting cefditoren MIC of 0.25 mg/ml. The maximal effect
(maximal reduction in initial inocula) was $94% for all strains,
being $99.9% for strains exhibiting cefditoren MIC of 0.25 mg/
ml.
Cefditoren, with a T.MIC of 77.6% and fT.MIC of 23.7%
maintained at 24h its bactericidal activity ($99.9% reduction)
against strains with cefditoren MIC=0.25 mg/ml (S1 and S2).
Against strains inhibited by 0.5 mg/ml cefditoren, with T.MIC of
61.6% and fT.MIC of 1.7%, cefditoren reduced in 90–97% the
initial inocula of S3 and S4 (penicillin MIC of 0.5 mg/ml), and in
45.1% (at 12h) and up to 85.0% (at 24h) the initial inocula of S5
(penicillin MIC of 1 mg/ml). Against strain S6 (penicillin MIC of
4 mg/ml), cefditoren produced a reduction in initial inocula of
91.8% at 12h but, due to the subsequent regrowth, of 52.9% at
24h.
Discussion
The dominant pharmacodynamic index determining effects of
b-lactams against S. pneumoniae is the time that drug concentrations
remains over the MIC, and determining the size of this
pharmacodynamic index for predicting optimal antibacterial
activity is critical and helps to determine dosing regimens,
breakpoints, and hence relevant clinical resistance [16]. The
magnitude of the parameter predicting the maximal effect in vivo
intuitively depends on inoculum, strain, protein binding, and
immune status.
To our knowledge this is the first study experimentally
analysing, from a dynamic point of view, the impact of protein
binding on the antipneumococcal activity of an antibiotic, by using
an in vitro pharmacodynamic system with a matrix mimicking the
physiological situation. This matrix consisted in 25% broth and
75% human serum, and contained 4.85 g/dl human albumin, a
value in the upper limit of the normal range in humans (3.5–5 g/
dl), with a constant physiological pH value of 7.4–7.8. With respect
to bacterial growth, this media in simulations without antibiotics
supported adequate growth of the S. pneumoniae strains along the
simulation period. Some key differences between in vivo and in
vitro pharmacokinetic models are the inoculum (bacterial load),
usually higher in in vitro models [16], and the absence of immune
system in in vitro models. However it can be postulated that the
absence of immune system is compensated by the microorganism
clearance from one-compartment systems. In this study we used a
high inoculum to more closely mimic human infection, and a one-
compartment model with a favourable ratio of multiplication rate/
clearance of the microorganism from the system with the media
used (controls in Figure 2).
With respect to the antibiotic, experimental protein binding of
cefditoren in the matrix was 87.1%, a rate comparable with that
described in humans (88%) in the literature [13]. Although pH
does not appear to be an issue in cephalosporin protein binding
Figure 1. Cefditoren concentrations: Mean6SD target (grey
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values of 7.4–7.8.
With respect to the strains used, although there are not CLSI
defined breakpoints for cefditoren [18], according to FDA
proposed breakpoints (#0.125 mg/ml for susceptibility and
$0.50 mg/ml for resistance [19]) two strains should be considered
as intermediate (cefditoren MIC of 0.25 mg/ml) and four resistant
(cefditoren MIC of 0.5 mg/ml).
Despite the experimentally confirmed high rate of cefditoren
protein binding, in the present simulations cefditoren decreased
.99.9% initial inocula (3 log10 reduction; bactericidal activity)
from 6h on of strains exhibiting cefditoren MIC of 0.25 mg/ml.
These reductions were obtained with T.MIC of 77.6% (a value
higher than the 40% predictive value for clinical cure in humans
[10]), but fT.MIC of 23.7%, a value lower than the 33%
classically considered for bacteriostatic effect [9]. With respect to
strains exhibiting cefditoren MIC of 0.5 mg/ml, a maximal effect
of initial inocula reduction ranging from 94.0 to 99.8% (higher
than inhibitory effect) was obtained with a T.MIC of 61.6%, but
f T.MIC of only 1.7%. The results of this study suggest that, from
the pharmacodynamic perspective, the presence of physiological
albumin concentrations does not preclude activity of cefditoren
physiological concentrations over the dosing interval against the
high inocula of the strains tested.
Allstrains,butstrainS6,exhibitedinitialinoculareductionshigher
at 24h than at 12h, reaching at the end of the experiment bactericidal
activity in the case of the strains with 0.25 mg/ml and initial inocula
reductions from 85.0% to 96.8% in the case of the three penicillin
intermediate resistant strains exhibiting cefditoren MIC of 0.5 mg/
ml. This suggests that against these latter strains additional doses in
the model (simulating bid regimens for 48h or 72h) may result in
higher effect, probably reaching the bactericidal end-point.
The situation is completely different with S6, the strain
exhibiting cefditoren MIC of 0.5 mg/ml that was penicillin-
resistant (MIC=4 mg/ml). This strain, as the others, exhibited the
same MIC values pre- and post-simulation, but can be considered
Table 1. Mean reduction of initial inocula: Time to obtain 90%, 99% and 99.9% reductions (T90%,T 99% and T99.9%), maximal
effect (maximal reduction in percentage within the dosing interval: 0-12h) and percentage of reduction at 12h and 24h.
Strain









S1 (0.12) 0.25 77.6 23.7 5.5610
7 3h 4h 6h .99.9 99.6 .99.9
S2 (0.25) 0.25 77.6 23.7 2.5610
7 3h 4h 6h .99.9 98.1 .99.9
S3 (0.5) 0.5 61.6 1.7 5.5610
7 2h 4h - 99.8 94.2 96.8
S4 (0.5) 0.5 61.6 1.7 4.8610
7 6h - - 94.3 90.7 96.6
S5 (1) 0.5 61.6 1.7 5.5610
7 6h - - 94.0 45.1 85.0
S6 (4) 0.5 61.6 1.7 1.9610
7 6h - - 98.4 91.8 52.9
PEN=penicillin, CDN=cefditoren.
T.MIC: % dosing interval with total cefditoren concentrations over MIC. fT.MIC: % dosing interval with free-cefditoren concentrations over MIC.
doi:10.1371/journal.pone.0002717.t001
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because of the regrowth that occurred from 12h (91.8% initial
inocula reduction) to 24h (52.9% reduction), thus not expecting
bactericidal activity with bid regimens for 48h or 72h). This
regrowth pattern was observed with amoxicillin/clavulanic acid in
highly penicillin-resistant strains [20], and is attributable to
defective lysis that is more prevalent in penicillin-resistant
pneumococci [21]. Tolerance is attributable to changes in
autolysin activity control rather than to survival after bactericidal
doses [21].
‘‘Susceptibility’’isclassicallydefined aspathogenlikelyinhibition
by blood concentrations, and ‘‘resistance’’ as pathogen not likely
inhibited by blood concentrations usually achieved [18,19]. If the
results obtained in this study are confirmed with different penicillin-
resistant serotypes, and provided there is clinical evidence of
eradication, strains exhibiting 0.25 and 0.5 mg/ml cefditoren MICs
may not be considered as non-susceptible because physiological
cefditorenconcentrationsalong24h(aftera400 mgbidregimen),in
a media where its protein binding was 87.1%, were bactericidal in
the first case and in the second produced not simple inhibition and
were more than bacteriostatic.
Materials and Methods
Strains
Six penicillin non-susceptible S. pneumoniae isolates of different
serotypes from the Spanish Pneumococcal Reference Laboratory
(Instituto de Salud Carlos III) were used throughout this study.
Strains were chosen on the basis of cefditoren MIC values
matching cefditoren MIC50 and MIC90 values for penicillin non-
susceptible strains in previous studies [11,12,22]: two strains with
cefditoren MIC of 0.25 mg/ml and four strains with cefditoren
MIC of 0.5 mg/ml. Serotypes and penicillin MIC for the strains
were: S1 (serotype 15A; 0.12 mg/ml), S2 (serotype 6B; 0.25 mg/
ml), S3 (serotype 19F; 0.5 mg/ml), S4 (serotype 6A; 0.5 mg/ml), S5
(Non-typable; 1 mg/ml), and S6 (serotype 9V; 4 mg/ml).
Prior and after the simulation process, MICs were determined
in quintuplicate using broth microdilution method following CLSI
recommendations [23], and modal values were considered.
Media
Culture media used in all pharmacokinetic/pharmacodynamic
(PK/PD) experiments consisted in a matrix of 75% non-heat
inactivated human serum (batch 01111695; Lonza Group Ltd,
Basel, Switzerland) and 25% Mueller-Hinton broth (Difco
laboratories, Detroit, Mi.) supplemented with 5% lysed sheep
blood (Difco laboratories) (HS-SMH), with a final pH of 7.7.
Previous experiments were performed to confirm that HS-SMH
was able to sustain the growth of S. pneumoniae.
Broth and agar Mueller-Hinton supplemented with 5% lysed
sheep blood were used for susceptibility tests and recovery of viable
bacteria in PK/PD experiments.
In vitro kinetic model
A one-compartment dynamic model was used to expose
bacteria to changing study drug concentrations [24]. The system
is represented by three connected flask: (i) a fresh media reservoir
containing HS-SMH (ii) a central flask with multiple ports for
addition and removal of broth, delivery of the antibiotic, and
collection of bacterial and antibiotic samples, containing media
plus bacterial culture, and (iii) a waste compartment. A computer-
controlled syringe pump (402 Dilutor Dispenser; Gilson S.A,
Villiers-le-Bel, France) infused the drug into the central flask until
the Cmax was reached. The exponential decay of antibiotic
concentrations was achieved by a continuous dilution-elimination
process using computerized peristaltic pumps (Masterflex, Cole-
Parmer Instrument Co., Chicago, Ill.) at a rate of 0.45 ml/min, set
to simulate the half-live of cefditoren [25,26] in humans. The same
flow rate for media removal allowed a constant volume all over the
simulation. The entire model was maintained at 37uC during the
simulation process with magnetic stir bars in the media to allow for
continuous mixing. Growth controls experiments, were performed
in the same conditions without cefditoren.
Kinetic simulations
The pharmacokinetic profile in serum after oral cefditoren-
pivoxil 400 mg bid [25,26,27] was simulated over 24h. Target
pharmacokinetic parameters, based on mean values reported in
humans [25,26,27], were Cmax=4.09 mg/ml, Tmax=2.67h, t1/
2=1.53h, and AUCall=14.28 mg/ml6h.
Experimental protein binding and albumin
concentrations
Cefditoren protein binding in HS-SMH was measured by an
ultrafiltration method described by Craig and Suh [17]. Cefditoren
wasadded toHS-SMHatconcentrationsof4 (concentration similar
to Cmax), 0.5, and 0.125 mg/ml. A 1-ml aliquot of each sample was
transferred to a centrifugal system device (CentrifreeH, Amicon
Bioseparations, Millipore, Tullagreen, Ireland) and was centrifuged
at 1,200 g for 15 min at room temperature in a Beckman fixed-
angle rotor centrifuge (model L8-55, Beckman Instrument, Full-
erton, CA, USA). Cefditoren concentrations in pre-filtered samples
and in ultrafiltrates recovered in the polyethylene filtrate cups, were
measuredbybioassay(see below).Percentage ofcefditorenboundto
proteins in HS-SMH was calculated using the expression:
½cefditoren in pre   filtered samples 
 ½cefditoren in ultrafiltrated samples 
=½cefditoren in pre   filtered samples |100:
Protein binding studies were conducted in triplicate for each
drug concentration examined.
Figure 3. Mean changes in initial inocula at the end of dosing
intervals: Decrease in log10 cfu/ml initial inocula in antibiotic
simulations at 12h (solid grey) and 24h (solid black); or
increase in log10 cfu/ml initial inocula in antibiotic-free
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measured at 0, 12 and 24h by the bromcresol green method [28].
Pharmacokinetic analysis
Simulated cefditoren concentrations were measured in samples
(0.5 ml) taken at 1, 2, 2.67 (target Tmax), 3, 4, 6, 8, 10, 12 and 24h
in triplicate by bioassay [29] using Morganella morganii ATCC
8076H as indicator organism [30]. Plates were inoculated with an
even lawn of indicator organism and incubated for 18 to 24h at
37uC. Standards and dilutions were prepared in HS-SMH and in
saline as protein-free control solution for ultrafiltrated samples
(lineal concentrations from 0.015 to 4 mg/ml (r.0.99); limit of
detection=0.015 mg/ml). Intra-day and inter-day coefficient of
variations were 5.83% and 3.16% for a concentration of 0.75 mg/
ml in HS-SMH and 2.83% and 3.55% in saline, respectively.
Antimicrobial concentrations were analyzed by a non-compart-
mental approach using WinNonlin 5.2 Professional program
(Pharsight, Mountainview, Ca.). Cmax and Tmax were obtained
directly from observed data and the area under the concentration-
time curve (AUC0–12) was calculated by the linear-log trapezoidal
rule. Both total and free-drug concentrations (according to protein
binding in HS-SMH) were considered throughout the study. The
cumulative percentage of a 24 h period that drug concentrations
exceeded the MIC for total (T.MIC) and unbound concentra-
tions (fT.MIC) expressed as percentage of the dosing interval,
were calculated by a non-compartmental approach for pharma-
codynamic data using the model 220 of WinNonlin program.
Measurement of antibacterial effect
Colonies from an overnight culture were allowed to grow in
Mueller-Hinton broth supplemented with 5% lysed sheep blood to
a density ranging from 1610
8 to 2610
8 cfu/ml, as measured by a
UV- spectrophotometer (Hitachi U-1100). A 6 ml aliquot of this
bacterial suspension were added into the central flask containing
60 ml of a 37uC atempered HS-SMH one hour before the
simulation process to allow the microorganism adaptation to the
medium. Initial inocula in all simulations ranged between 2610
7–
6610
7 cfu/ml. Samples (0.5 ml) were collected at 0, 1, 2, 3, 4, 6, 8,
10, 12 and 24h, and serially diluted in 0.9% sodium chloride. At
least four dilutions of each sample were spread (20 ml) onto
Mueller-Hinton agar supplemented with 5% sheep blood and
overnight incubated for colony counting. The limit of detection
was 50 cfu/ml. Each experiment was performed in triplicate.
Changes in viable counts between time 0 and the different
timepoints were calculated and expressed as percentage of
reduction. Times to obtain 90% (T90%), 99% (T99%) and 99.9%
(T99.9%) reductions were determined.
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